12-Month Study of Arimoclomol Showed a Clinically Meaningful Treatment Effect, Corresponding to a Reduction in Disease Progression Highlights Arimoclomol is Under Regulatory Review in Europe...
OCALA, Fla., July 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test...
hVIVO to develop challenge agent based on new COVID-19 variants Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services contract research organisation (CRO) and world...
CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that...
Call for volunteers to enroll in studies that will play a key part in developing effective vaccines and treatments for COVID-19 Open Orphan plc (AIM: ORPH), a rapidly growing specialist...
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories...
Highlights Orphazyme’s Establishment of U.S. Headquarters in Chicago and Recruitment of More Than 30 U.S. Employees Comments That Orphazyme’s Investments in the U.S. are Intended to Support...
Highlights Orphazyme’s Establishment of U.S. Headquarters in Chicago and Recruitment of More Than 30 U.S. Employees Comments That Orphazyme’s Investments in the U.S. are Intended to Support...
Orphan Medical, Inc. (NASDAQ:ORPH) announced that its stockholders, voting at a special meeting held this morning, have approved the proposed acquisition of the Company by Jazz Pharmaceuticals...
Orphan Medical Sees Lead Product Growing to $20 Million This Year MINNEAPOLIS, Feb. 23 /PRNewswire-FirstCall/ -- Orphan Medical, Inc.'s (NASDAQ:ORPH) chief executive officer John Bullion believes...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관